Les cookies nous permettent de vous proposer nos services plus facilement. En utilisant nos services, vous nous donnez expressément votre accord pour exploiter ces cookies.En savoir plus OK

SOMMAIRE COVID-19 CORONAVIRUS - SOMMAIRE "NATURE"

SOMMAIRE COVID-19 CORONAVIRUS - SOMMAIRE "NATURE"

Le pdf se trouve ci-dessous. Vous pouvez télécharger le pdf en cliquant à droite.

Revenir à l'accueil

COLLECTION 

Coronavirus

To support urgent research to combat the ongoing outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2, the editorial teams at Nature Research have curated a collection of relevant articles. Our collection includes research into the basic biology of… 

Latest SARS-CoV-2/COVID-19 research

Respiratory virus shedding in exhaled breath and efficacy of face masks

A study of 246 individuals with seasonal respiratory virus infections randomized to wear or not wear a surgical face mask showed that masks can significantly reduce detection of coronavirus and influenza virus in exhaled breath and may help interrupt virus transmission.

  • Nancy H. L. Leung, 
  • Daniel K. W. Chu ⋯ 
  • Benjamin J. Cowling

BRIEF COMMUNICATIONNature Medicine

Structural basis of receptor recognition by SARS-CoV-2

The crystal structure of the receptor-binding domain of the SARS-CoV-2 spike in complex with human ACE2 sheds light on the structural differences compared with the receptor-binding domain of SARS-CoV that increase its binding affinity to ACE2.

  • Jian Shang, 
  • Gang Ye ⋯ 
  • Fang Li

ARTICLEOPEN ACCESSNature

News and Comment

Could BCG be used to protect against COVID-19?

Nearly 100 years since it was first used in humans as a vaccine for tuberculosis, Bacillus Calmette–Guérin (BCG) has been suggested as a possible agent to prevent coronavirus disease 2019 (COVID-19). A number of studies are underway to investigate this possibility… 

  • Gil Redelman-Sidi

COMMENTNature Reviews Urology

The need for urogenital tract monitoring in COVID-19

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which invades a cell through binding to the ACE2 receptor and TMPRSS2 priming. Patients with severe disease predominantly present with pneumonia-related symptoms.… 

  • Shangqian Wang, 
  • Xiang Zhou ⋯ 
  • Zengjun Wang

COMMENTNature Reviews Urology

Crowdsourcing a crisis response for COVID-19 in oncology

Crowdsourcing efforts are currently underway to collect and analyze data from patients with cancer who are affected by the COVID-19 pandemic. These community-led initiatives will fill key knowledge gaps to tackle crucial clinical questions on the complexities of… 

  • Aakash Desai, 
  • Jeremy Warner ⋯ 
  • Gilberto Lopes

COMMENTNature Cancer

Provision of cancer care during the COVID-19 pandemic

Health-care services are rapidly transforming their organization and workforce in response to the coronavirus disease 2019 (COVID-19) pandemic. These changes, and a desire to mitigate infection risk, are having profound effects on other vital aspects of care,… 

  • James Spicer, 
  • Charlotte Chamberlain & 
  • Sophie Papa

COMMENTNature Reviews Clinical Oncology

John-Arne Røttingen

Over 180 clinical trials of proposed COVID-19 drugs are already recruiting patients, and another 150 are registered to start recruiting patients soon. But many of these trials are small and not designed to identify the best treatment strategies for the COVID-19… 

  • Asher Mullard

AN AUDIENCE WITHNature Reviews Drug Discovery

On being human in the face of a pandemic

As the COVID-19 pandemic sweeps through the world, we must reassess the principles that guide our individual and collective responses and the way we operate in society. In the face of crisis, we must lead with science and humanity.

EDITORIALNature Cancer

Nanoscale nights of COVID-19

As the spread of SARS-CoV-2 has triggered worldwide closures of research labs and facilities, Kostas Kostarelos shares his views on what may be going wrong in the fight against COVID-19 and how the nanoscience community could and should contribute.

  • Kostas Kostarelos

THESISNature Nanotechnology

Minimizing the risk of COVID-19 among patients on dialysis

Patients on haemodialysis or peritoneal dialysis are likely to be at increased risk of novel coronavirus disease (COVID-19). Preventive strategies must be implemented to minimize the risk of disease transmission in dialysis facilities, including education of staff… 

  • T. Alp Ikizler & 
  • Alan S. Kliger

COMMENTNature Reviews Nephrology

COVID-19 in Africa

COVID-19 has started to reach Africa, a continent that has in recent decades faced the ongoing HIV/AIDS pandemic and the Ebola epidemic of 2014–2016. Dr Matshidiso Moeti, WHO Regional Director for Africa, talks to Nature Human Behaviour about the African response to COVID-19.

  • Charlotte Payne

Q&ANature Human Behaviour

Pandemics show us what government is for

Growth-at-any-cost economics has health costs, a reality the COVID-19 pandemic brings into sharp relief. Governments must manage the tension between economics and health, but they should not stray from their original mandate to protect people. Too much dependence on… 

  • Susan Erikson

WORLD VIEWNature Human Behaviour

When COVID-19 meets centralized, personalized power

The debate over whether autocracies or democracies are better at fighting epidemics is misguided. Under President Xi Jinping’s centralized command, his administration has both succeeded and failed at handling the COVID-19 crisis. While it effectively curbed… 

  • Yuen Yuen Ang

COMMENTNature Human Behaviour

Facing up to the uncertainties of COVID-19

The human tendency to impose a single interpretation in ambiguous situations carries huge dangers in addressing COVID-19. We need to search actively for multiple interpretations, and governments need to choose policies that are robust if their preferred theory turns… 

  • Nick Chater

WORLD VIEWNature Human Behaviour

Digital technology and COVID-19

The past decade has allowed the development of a multitude of digital tools. Now they can be used to remediate the COVID-19 outbreak.

  • Daniel Shu Wei Ting, 
  • Lawrence Carin ⋯ 
  • Tien Y. Wong

COMMENTNature Medicine

Combating COVID-19: health equity matters

COVID-19 has affected vulnerable populations disproportionately across China and the world. Solid social and scientific evidence to tackle health inequity in the current COVID-19 pandemic is in urgent need.

  • Zhicheng Wang & 
  • Kun Tang

COMMENTNature Medicine

Urology in the time of corona

The world is currently in the grip of the COVID-19 pandemic. Rapid changes in medical priorities are being enforced across all health-care systems. Urologists have had to reduce or halt their clinical activity and assist on COVID-19 wards. The repercussions on… 

  • Richard Naspro & 
  • Luigi F. Da Pozzo

COMMENTNature Reviews Urology

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet.… 

  • Weilong Shang, 
  • Yi Yang ⋯ 
  • Xiancai Rao

COMMENTOPEN ACCESSnpj Vaccines

COVID-19 and the cardiovascular system

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system.… 

  • Ying-Ying Zheng, 
  • Yi-Tong Ma ⋯ 
  • Xiang Xie

COMMENTNature Reviews Cardiology

Prevent and predict

As the COVID-19 outbreak continues, the next pandemic could be prevented by ending the wildlife trade and reinvesting in the monitoring of potential zoonoses.

EDITORIALNature Ecology & Evolution

We shouldn’t worry when a virus mutates during disease outbreaks

Mutation. The word naturally conjures fears of unexpected and freakish changes. Ill-informed discussions of mutations thrive during virus outbreaks, including the ongoing spread of SARS-CoV-2. In reality, mutations are a natural part of the virus life cycle and rarely impact outbreaks dramatically.

  • Nathan D. Grubaugh, 
  • Mary E. Petrone & 
  • Edward C. Holmes

COMMENTNature Microbiology

Rapid outbreak response requires trust

As the international community responds to an outbreak of coronavirus-induced pneumonia in Wuhan, China, early and open data sharing — which are vital for its control — depend on the trust that the data will not be used without proper attribution to those who generated it.

EDITORIALNature Microbiology

Reviews and Perspectives

Defining trained immunity and its role in health and disease

Here a group of leaders in the field define our current understanding of ‘trained immunity’, which refers to the memory-type responses that occur in the innate immune system. The authors discuss our current understanding of the key epigenetic and metabolic processes… 

  • Mihai G. Netea, 
  • Jorge Domínguez-Andrés ⋯ 
  • Eicke Latz

REVIEW ARTICLENature Reviews Immunology

The trinity of COVID-19: immunity, inflammation and intervention

In the short time since SARS-CoV-2 infections emerged in humans, much has been learned about the immunological processes that underlie the clinical manifestation of COVID-19. Here, the authors provide an overview of the pathophysiology of SARS-CoV-2 infection and… 

  • Matthew Zirui Tay, 
  • Chek Meng Poh ⋯ 
  • Lisa F. P. Ng

REVIEW ARTICLENature Reviews Immunology

Translating IL-6 biology into effective treatments

In this Perspective article, the authors recount the earliest stages of translational research into IL-6 biology and the subsequent development of therapeutic IL-6 pathway inhibitors for the treatment of autoimmune rheumatic diseases and potentially numerous other indications.

  • Ernest H. Choy, 
  • Fabrizio De Benedetti ⋯ 
  • Tadamitsu Kishimoto

PERSPECTIVENature Reviews Rheumatology

Clinical metagenomics

Clinical metagenomic next-generation sequencing (mNGS) is rapidly moving from bench to bedside. This Review discusses the clinical applications of mNGS, including infectious disease diagnostics, microbiome analyses, host response analyses and oncology applications.… 

  • Charles Y. Chiu & 
  • Steven A. Miller

REVIEW ARTICLENature Reviews Genetics

Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is the rapid onset of noncardiogenic pulmonary oedema, hypoxaemia and the need for mechanical ventilation in hospitalized patients. This Primer describes the risk factors for ARDS, the underlying pulmonary damage and repair… 

  • Michael A. Matthay, 
  • Rachel L. Zemans ⋯ 
  • Carolyn S. Calfee

PRIMERNature Reviews Disease Primers

Tracking virus outbreaks in the twenty-first century

This Review Article describes how recent advances in viral genome sequencing and phylogenetics have enabled key issues associated with outbreak epidemiology to be more accurately addressed, and highlights the requirements and challenges for generating, sharing and… 

  • Nathan D. Grubaugh, 
  • Jason T. Ladner ⋯ 
  • Kristian G. Andersen

REVIEW ARTICLENature Microbiology

Origin and evolution of pathogenic coronaviruses

Coronaviruses have a broad host range and distribution, and some highly pathogenic lineages have spilled over to humans and animals. Here, Cui, Li and Shi explore the viral factors that enabled the emergence of diseases such as severe acute respiratory syndrome and Middle East respiratory syndrome.

  • Jie Cui, 
  • Fang Li & 
  • Zheng-Li Shi

REVIEW ARTICLENature Reviews Microbiology

The phylogenomics of evolving virus virulence

The virulence of viruses is a major determinant of the health burden of viral infections in humans and other species. In this article, Geoghegan and Holmes discuss how largely disparate research fields — theoretical modelling of virulence evolution and experimental… 

  • Jemma L. Geoghegan & 
  • Edward C. Holmes

REVIEW ARTICLENature Reviews Genetics

ISG15 in antiviral immunity and beyond

Ubiquitin-like protein ISG15 is an interferon-induced protein that has been implicated as a central player in the host antiviral response. In this Review, Perng and Lenschow provide new insights into how ISG15 restricts and shapes the host response to viral… 

  • Yi-Chieh Perng & 
  • Deborah J. Lenschow

REVIEW ARTICLENature Reviews Microbiology

Related research

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Remdesivir (RDV) is a broad-spectrum antiviral drug with activity against MERS coronavirus, but in vivo efficacy has not been evaluated. Here, the authors show that RDV has superior anti-MERS activity in vitro and in vivo compared to combination therapy with… 

  • Timothy P. Sheahan, 
  • Amy C. Sims ⋯ 
  • Ralph S. Baric

ARTICLEOPEN ACCESSNature Communications

Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform

Rachel Graham et al. show that coronaviruses with extensively rewired transcription regulatory networks are effective vaccine candidates against Severe Acute Respiratory Syndrome Coronavirus. The reversion of live-attenuated vaccine strains to virulence can be avoided with these vaccines.

  • Rachel L. Graham, 
  • Damon J. Deming ⋯ 
  • Ralph S. Baric

ARTICLEOPEN ACCESSCommunications Biology

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

Corticosteroid therapy is frequently used for chronic obstructive pulmonary disease (COPD) but its use is associated with increased risk of pneumonia. Here the authors show that corticosteroid use impairs innate and adaptive immunity to rhinovirus infection, which is restored by exogenous IFNβ.

  • Aran Singanayagam, 
  • Nicholas Glanville ⋯ 
  • Sebastian L. Johnston

ARTICLEOPEN ACCESSNature Communications

Voir également :

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/Comment-beneficier-de-l-aide-defiscalisee-du-fonds-de-solidarite-finance-par-l-Etat-et-les-regions.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/DISPOSITIF-EXCEPTIONNEL-D-ACTIVITE-PARTIELLE.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/Deconfinement-100-km.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/Enfants-ecoles-et-environnement-familial-dans-le-contexte-de-la-crise-COVID-19.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/LE-FONDS-DE-SOLIDARITE-Quelles-demarches-pour-quelles-entreprises-Dossier-de-presse-Mardi-31-mars-2020-Coronavirus-Covid-19.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/Votre-perimetre-de-deplacement-a-100-kilometres.html

http://audentia-gestion.fr/COVID-19/DOCUMENTATION/YVELINES-Plan-d-aide-d-urgence-face-a-la-crise-sanitaire-du-COVID-19-27-millions-d-euros.html

Au format "Texte" :

371 editorial On being human in the face of a pandemic As the COVID-19 pandemic sweeps through the world, we must reassess the principles that guide our individual and collective responses and the way we operate in society. In the face of crisis, we must lead with science and humanity. I t has been three short months since a pneumonia of unknown cause was first reported in the city of Wuhan in the Hubei province of China. Yet at the time of this writing, in early April 2020, the number of COVID-19 cases is nearing 1.5 million worldwide, with >87,000 fatalities and over 3 billion people under some form of stay-at-home orders. Pandemics are certainly not a new occurrence in human history, with the H1N1 influenza pandemic of 2009 being particularly fresh in memory. The quality and sophistication of modern medicine and technology are at their peak. Furthermore, we live in an era of rapid and efficient global communication and collaboration of nations. And yet the causative coronavirus, SARS-CoV-2, is sweeping through the world with a devastating death toll, bringing healthcare systems to a breaking point, grounding half the global population and shattering our perceptions of normality. The forensic analysis of how we got to this point will have to wait while we fight this crisis. Suffice it to say that the combination of a rapidly disseminating new virus and a toxic mix of political vacillation and opportunism, misinformation, weak health systems and science denialism created the perfect storm. This pandemic has been an urgent wake-up call for many high-income countries, as it has brought to the fore the fragility of their healthcare systems, not because their otherwise well-equipped and well-staffed hospitals did not have stockpiles of thousands of ventilators, but because they failed to mount a rapid and decisive response to protect their citizens on a political level. The lack of clear, science-driven guidance, effective testing and early planning to procure the necessary medical equipment despite the mounting evidence that we were facing a global health emergency has been especially shocking in the USA, EU and UK. Despite priding themselves on the power of their respective unions, quality of science and medical expertise, and economic strength, they each failed spectacularly in their initial response to the pandemic, coming across at best as unprepared and at worst as naïve and uninformed. This lack of preparedness has unfortunately placed vulnerable parts of the population at greater risk, not just of contracting this infection but also of potentially being unable to receive essential care for other serious conditions, including cancer, should hospitals become inundated with patients with COVID-19. With powerhouses such as the USA, EU and UK floundering and unable to coordinate a unified, effective response, how lower-income countries with already compromised health systems will face this challenge and whether the necessary international support will be forthcoming have become pressing questions. Yet some continue to characterize this virus as ‘the great equalizer’. The facts say it is nothing of the sort. Beyond the differences in how people respond to the infection itself, COVID-19 has accentuated the differences between the haves and the have-nots. As part of the population shelters in place in comfortable homes, many others reside in cramped living spaces or are homeless. While many of us have been readjusting to a work-from-home reality and may be worrying about stalled careers and missed professional opportunities, many others are essential workers who now face increased risks to keep key services up and running— not to mention the large numbers of people who are losing their livelihoods as the economy continues to crash, or those who were already relying on external help to get by. Moreover, curtailing social activities and human interaction has revealed the gulf between those who, surrounded by their family, are anxious to keep them safe, and those who are alone and have been left even more isolated. While the needs and anxieties of every person are valid, it is essential to recognize that certain parts of the population bear a disproportionate burden of this crisis and need our support and protection as a priority. Unfortunately, the pervasive view, especially at earlier stages of the pandemic, that only those with underlying conditions or of older age were vulnerable, revealed instead an alarming degree of ableism and ageism in our society. Stories abound of people who, lacking a modicum of social responsibility or self-control, refused to follow social-distancing guidelines and thereby endangered themselves and others. More disturbing, however, have been the state-level ideas of relying on the development of naturally acquired herd immunity or of focusing on jumpstarting the economy before achieving outbreak containment. Both strategies would come at a huge cost of human life, given the current absence of reliable point-of-care testing to distinguish carriers from recovered or healthy people. At the opposite end of the spectrum lies the response of those in the medical and scientific communities, who have been a beacon of solidarity, resilience and action. The doctors, nurses and all other healthcare workers who, faced with unprecedented challenges, are bearing the brunt of this pandemic on the front lines have been nothing short of inspiring. Moreover, despite the fact that the routine research enterprise has come to an abrupt halt, with many laboratories in several countries now closed, researchers have also rallied to fight the pandemic. Scientists from around the world have rapidly diverted efforts toward all aspects of COVID-19 work, from basic biology and immunology to diagnostic testing, vaccines and therapeutic interventions. Volunteers have been offering their skills as part of international collaborations, and shuttered labs have been donating reagents and essential lab and personal protective equipment. Others have been making the most of their digitally confined existence by applying their expertise to parse the rapidly expanding SARS-CoV-2 literature, distilling and disseminating knowledge to other scientists and the general public. If there is a silver lining in this challenging situation, it is seeing this community spirit flourish and also experiencing the shift of an often science-skeptic public, who are now turning to scientists and doctors with renewed trust. It is essential to maintain this renewed focus by the public and governments on science, medicine and technology even after the threat of COVID-19 is addressed. “Man is the measure of all things,” said the ancient Greek philosopher Protagoras. Setting aside the philosophical debate that surrounds this anthropocentric view of the universe, the message is particularly apt today, when the world is in the throes of the COVID-19 pandemic. Each human experience, and by extension each human life, is unique, equally valid and precious. During these tumultuous times, we need to remember this and join efforts to lead with science and humanity. ❐ Published online: 9 April 2020 https://doi.org/10.1038/s43018-020-0062-2 Nature Cancer | VOL 1 | April 2020 | 371 | www.nature.com/natcancer LE FONDS DE SOLIDARITE Quelles démarches pour quelles entreprises? Dossier de presse Mardi 31 mars 2020 CORONAVIRUS COVID-19 FAQ – Fonds de solidarité 1. Le fonds de solidarité, c’est quoi ? 2. Qui finance le fonds de solidarité ? 3. Qui bénéficie de ce fonds de solidarité ? 4. Quelles démarches pour bénéficier du fonds de solidarité ? 5. Toutes les entreprises qui font la demande auront automatiquement 1 500 euros ? 6. Pourquoi plafonner l’aide à 1500 euros ? 7. Comment faire si j’ai créé mon activité après le mois de mars 2019 ? 8. Pourquoi se limiter aux entreprises qui ont une baisse de chiffre d’affaires de 70% ou plus ? 9. Pourquoi le deuxième volet du fonds est-il limité aux entreprises qui comptent au moins 1 salarié ? 10. Le fonds de solidarité sera-t-il renouvelé pour le mois d’avril ? 1. Le fonds de solidarité, c’est quoi ? C’est un fonds créé par l’Etat et les Régions pour prévenir la cessation d’activité des très petites entreprises (TPE), micro-entrepreneurs, indépendants et professions libérales, qui ont 10 salariés au plus, un chiffre d’affaires annuel inférieur à 1 million d’euros et un bénéfice annuel imposable inférieur à 60 000 euros, particulièrement touchées par les conséquences économiques du covid-19. Il s’agit d’entreprises qui ont fait l’objet d’une interdiction d’accueil du public selon l’article 8 du décret du 23 mars 2020, même s’il y a une activité résiduelle telle que la vente à emporter, la livraison et les retraits de commandes, « room service » ou d’une perte de chiffre d’affaires d’au moins 50 % en mars 2020 par rapport à mars 2019. Ce fonds de solidarité permet de verser une aide directe aux entreprises concernées en complément d’autres mesures ou d’autres aides qu’elles peuvent avoir par ailleurs. Le fonds comporte deux volets : Le premier volet permet à l’entreprise de bénéficier d’une aide d’un montant égal à la perte déclarée de chiffre d’affaires en mars 2020, dans la limite de 1 500 €. La référence pour le calcul de la perte de chiffre d’affaires est précisée dans le tableau ci-dessous : Entreprises existantes au 1 er mars 2019 Chiffre d’affaires du mois de mars 2019 Entreprises créées après le 1er mars 2019 Chiffre d’affaires mensuel moyen entre la date de création et le 1er mars 2020 Entrepreneur ayant bénéficié d’un congé pour maladie, accident du travail ou maternité en mars 2019 Chiffre d’affaires mensuel moyen entre le 1er avril 2019 et le 1er mars 2020 Le second volet permet aux entreprises qui bénéficient du premier volet de percevoir une aide complémentaire forfaitaire de 2000 € lorsque :  elles se trouvent dans l’impossibilité de régler leurs créances exigibles à trente jours ;  elles se sont vues refuser un prêt de trésorerie d’un montant raisonnable par leur banque. Pour en faire la demande, l’entreprise doit avoir au moins un salarié. Les régions seront en charge de l’instruction de ce deuxième volet. 2. Qui finance le fonds de solidarité ? Le fonds est financé par l’Etat, les Régions et les collectivités d’outre-mer. Il est ouvert aux contributions d’autres collectivités et de donateurs privés. Les compagnies d’assurance ont déjà annoncé une contribution de 200 millions d’euros. 3. Qui bénéficie de ce fonds de solidarité ? Ce fonds s’adresse aux commerçants, artisans, professions libérales et autres agents économiques, quel que soit leur statut (société, entrepreneur individuel, association…) et leur régime fiscal et social (y compris micro-entrepreneurs), ayant :  un effectif inférieur ou égal à 10 salariés ;  un chiffre d’affaires sur le dernier exercice clos inférieur à 1 000 000€ ;  un bénéfice imposable inférieur à 60 000 €. Leur activité doit avoir débutée avant le 1er février 2020 et il ne doit pas y avoir eu de déclaration de cessation de paiement avant le 1er mars 2020. Par ailleurs, les titulaires d’un contrat de travail ou d’une pension de retraite et les entrepreneurs ayant bénéficié d’au moins deux semaines d’arrêt maladie en mars ne sont pas éligibles. 4. Quelles démarches pour bénéficier du fonds de solidarité ? Pour le premier volet de l’aide : A partir du mardi 31 mars 2020, toutes les entreprises éligibles ayant fait l’objet d’une fermeture administrative ou ayant subi une perte de chiffre d’affaires de plus de 70% en mars 2020 par rapport à mars 2019 pourront faire leur demande sur le site impots.gouv.fr en renseignant les éléments suivants : SIREN, SIRET, RIB, chiffre d’affaires, montant de l’aide demandée, déclaration sur l’honneur. A partir du vendredi 3 avril 2020, toutes les entreprises éligibles ayant subi une perte de chiffre d’affaires de plus de 50% en mars 2020 par rapport à mars 2019 pourront également faire une déclaration sur le site impots.gouv.fr pour recevoir une aide défiscalisée allant jusqu’à 1 500 euros. La DGFiP effectuera des contrôles de premier niveau et versera l’aide rapidement au demandeur. Des contrôles de second niveau pourront être effectués par la DGFiP postérieurement au versement de l’aide. Pour le second volet de l’aide : A partir du 15 avril 2020, l’entreprise se rendra sur une plateforme ouverte par la région dans laquelle ils exercent leur activité. Afin que les services de la région puissent examiner la demande, l’entreprise joindra une estimation étayée de son impasse de trésorerie, une description succincte de sa situation démontrant le risque imminent de faillite ainsi que le nom de la banque dont l’entreprise est cliente lui ayant refusé un prêt de trésorerie d’un montant raisonnable, le montant du prêt demandé et son contact dans la banque. L’aide sera versée par la DGFiP. 5. Toutes les entreprises qui font la demande auront automatiquement 1 500 euros ? Si l’entreprise remplit les conditions d’octroi de l’aide versée au titre du premier volet, elle percevra automatiquement une aide défiscalisée couvrant sa perte de chiffre d’affaires et allant jusqu’à 1 500 euros. 6. Pourquoi plafonner l’aide à 1500 euros ? Le fonds a été paramétré de manière à soutenir un maximum d’entreprises et de commerce, en vue de couvrir leurs frais fixes pour la période sur laquelle elles sont impactées. Pour rappel, l’aide mise en place par l’Etat ne se limite pas à ce seul fonds et de nombreuses mesures sont en place, telles que notamment l’indemnisation du chômage partiel des salariés, le report des échéances sociales et fiscales, ou encore la garantie des prêts de trésorerie. 7. Comment faire si j’ai créé mon activité après le mois de mars 2019 ? S’il est impossible de comparer le niveau d’activité entre mars 2019 et mars 2020, alors la comparaison se fera entre le niveau de chiffre d’affaires en mars 2020 et la moyenne mensuelle du chiffre d’affaires sur les mois d’activité depuis la création de l’entreprise 8. Pourquoi le deuxième volet du fonds est-il limité aux entreprises qui comptent au moins 1 salarié ? Le deuxième volet du fonds, instruit sur dossier par les régions, est un dispositif « anti-faillite » pour les très petites entreprises qui, malgré les différentes mesures déployées par le gouvernement, seraient encore en risque de défaillance en raison principalement de leurs frais fixes. 9. Le fonds de solidarité sera-t-il renouvelé pour le mois d’avril ? Le fonds de solidarité a été abondé pour le mois de mars et sera renouvelé pour le mois d’avril.